Ethisphere Magazine

magazine cover

Council Log-in

Username

Password

Ethisphere Magazine Features

features

2020 Global Sustainability Centers

// read more...

What Goes Up must Come Down, for the Sake of the Environment

// read more...

No Cash Required: the Foreign Corrupt Practices Act and Corporate Risk

// read more...

What Do You Mean I’m a Lobbyist

// read more...

Sustainability Reporting: Beyond the Core and into the Supply Chain

// read more...

Can You Teach Ethics to the Big Bank?

// read more...

Working Together to Improve the Supply Chain

// read more...

Knowledge, Commitment and Experience - Lead the Way

// read more...

The Intricacies of Screening International Business Partners - An Emerging Market Perspective

// read more...

Ethical Supply Chains: Creating an Effective Supplier Code of Conduct

// read more...

Embracing Controversy

// read more...

DOJ’s Rising Expectations

// read more...

Global Compliance - Brazil

// read more...

50 Codes of Conduct Benchmarked - Q3 2008

// read more...

Bribeline: Bribe Demands in China

// read more...

Bribery: Winning Essay

// read more...

Big Shot CEO’s EthiGear Selection Q3 - 2008

// read more...

Good + The Bad

// read more...

CYA-Call Your Attorney

// read more...

  • January 19-22: Beacon Event - Anti-Corruption Asia Congress (Hong Kong)// Click here
  • February 1-2: MarcusEvans - Corporate Fraud Control// Click here
  • February 4-5: Global Ethics Summit - 2009 Global Ethics Summit // Click here

// More events

Global Ethics Summit

Judge rules AztraZeneca, Bristol-Meyers, and Schering-Plough priced “unethically”

July 14, 2007

A federal judge has ruled that pharmaceutical companies AstraZeneca, Schering-Plough Corp. and Bristol-Myers Squibb Co. engaged in unfair and deceptive trade practices regarding some of their drug prices.

The three companies, along with Johnson & Johnson, were defendants in a suit that alleged they inflated the average wholesale prices (AWP) that they reported and which are used by insurers as a benchmark to calculate drug reimbursements.

AstraZeneca was ordered to pay damages of $4.45 million to non-Medicare third-party payers and Bristol-Myers Squibb to pay damages of $183,000.

As the Wall Street Journal noted…

The judge asked for more information before deciding on further restitution to third-party payers for co-payments for some drugs. Plaintiffs’ attorney Steve Berman said the decision “positions the litigation very well for us. In our view, the companies are now on the hook.” Mr. Berman said the damages could be significant in the next round of the litigation. Plaintiffs will be seeking damages of $500 million from AstraZeneca, which could be doubled or tripled, per individual states’ laws.

Commentary: Everyone knows that the pharma industry is rife with questionable pricing and reimbursement practices - that’s not really news. However, these companies got caught and some even bigger judgments related to AWP are likely around the corner.

What is also interesting is that the judge on the case doesn’t just focus on “legal” and “illegal” in her judgment - but goes so far as to deem these three pharma companies are “unethical” in their pricing practices which in turn causes “real injuries to the insurers and patients” who are paying inflated prices for life-sustaining medications.

And finally, we want to point out specifically that Johnson & Johnson, which had been party to this suit, DID NOT VIOLATE THE LAW. We have been accused at Ethisphere of being too hard on Johnson & Johnson in the past (including by J&J itself) so we want to give credit where credit is due and note that this is a positive reflection on J&J.

Print This Post Print This Post

Note: Comments will be moderated for profanity.

Leave a Reply

*
To prove you're a person (not a spam script), type the security word shown in the picture.
Anti-Spam Image